Abstract
A practical synthetic route of DOPA derivative 2, which should be useful for direct biosynthetic production of potent antitumor natural products, saframycins and ecteinascidin 743 was established. The developed strategy features i) easy-to-handle reactions without special care upon both dryness and inert atmopsphere, and ii) the facile HPLC-free purification of 2 via recrystallization enabling scalable synthesis of 2.
Keywords: Biosynthesis, 3,4-dihydroxyphenylalanine, DOPA, ecteinascidin 743, non-natural amino acid, saframycin, bacteria, sarcoma, polypeptide, tyrosine
Letters in Organic Chemistry
Title: Practical Synthesis of DOPA Derivative for Biosynthetic Production of Potent Antitumor Natural Products, Saframycins and Ecteinascidin 743
Volume: 8 Issue: 10
Author(s): Kohei Torikai, Takayoshi Saruwatari, Tatsuya Kitano, Takuya Sano, Atsuko Nakane, Hiroshi Noguchi and Kenji Watanabe
Affiliation:
Keywords: Biosynthesis, 3,4-dihydroxyphenylalanine, DOPA, ecteinascidin 743, non-natural amino acid, saframycin, bacteria, sarcoma, polypeptide, tyrosine
Abstract: A practical synthetic route of DOPA derivative 2, which should be useful for direct biosynthetic production of potent antitumor natural products, saframycins and ecteinascidin 743 was established. The developed strategy features i) easy-to-handle reactions without special care upon both dryness and inert atmopsphere, and ii) the facile HPLC-free purification of 2 via recrystallization enabling scalable synthesis of 2.
Export Options
About this article
Cite this article as:
Torikai Kohei, Saruwatari Takayoshi, Kitano Tatsuya, Sano Takuya, Nakane Atsuko, Noguchi Hiroshi and Watanabe Kenji, Practical Synthesis of DOPA Derivative for Biosynthetic Production of Potent Antitumor Natural Products, Saframycins and Ecteinascidin 743, Letters in Organic Chemistry 2011; 8 (10) . https://dx.doi.org/10.2174/157017811799304160
DOI https://dx.doi.org/10.2174/157017811799304160 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Synthesis of Nano-Doxorubicin and its Anticancer Effect
Anti-Cancer Agents in Medicinal Chemistry Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery
Current Topics in Medicinal Chemistry Soft Matter Assemblies as Nanomedicine Platforms for Cancer Chemotherapy: A Journey from Market Products Towards Novel Approaches
Current Topics in Medicinal Chemistry Bladder Cancer and Stem Cells
Current Signal Transduction Therapy Recent Patents and Patent Applications Relating to mTOR Pathway
Recent Patents on DNA & Gene Sequences CD40L - A Multipotent Molecule for Tumor Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Differential Splicing, Disease and Drug Targets
Infectious Disorders - Drug Targets PSMA7, A Potential Biomarker of Diseases
Protein & Peptide Letters Brain Tumour Stem Cells: Implications for Cancer Therapy and Regenerative Medicine
Current Stem Cell Research & Therapy Research Progress of Exogenous Plant MiRNAs in Cross-Kingdom Regulation
Current Bioinformatics Hypoxia Signaling and the Metastatic Phenotype
Current Molecular Medicine Therapeutic Targeting of Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Medical Imaging Polypharmacology of Approved Anticancer Drugs
Current Drug Targets Killing the Messenger: Antisense DNA and siRNA
Current Drug Targets Novel Homeodomain Transcription Factor Nkx2.2 in the Brain Tumor Development
Current Cancer Drug Targets Exploring the Role of Nerve Growth Factor in Multiple Sclerosis: Implications in Myelin Repair
CNS & Neurological Disorders - Drug Targets Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes
Current Pharmaceutical Design Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases
Current Drug Targets Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy